Deutsche Märkte öffnen in 8 Stunden 3 Minuten

Pacific Edge Limited (PFGTF)

OTC Markets OTCPK - OTC Markets OTCPK Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
0,0600-0,0011 (-1,80%)
Börsenschluss: 01:09PM EDT

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

Sektor(en)Healthcare
BrancheDiagnostics & Research
Vollzeitmitarbeiter

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Peter MeintjesChief Executive OfficerN/AN/AN/A
Mr. Grant GibsonChief Financial OfficerN/AN/AN/A
Mr. Darrell MorganChief Operating OfficerN/AN/AN/A
Dr. Justin HarveyChief Technology OfficerN/AN/AN/A
Prof. Parry Guilford Ph.D.Chief Scientific Officer & Member of Scientific Advisory Board81,63kN/AN/A
Mr. Andrew McIntoshChief Digital OfficerN/AN/AN/A
Glen CostinPresident of Asia PacificN/AN/AN/A
Dr. Tamer AboushwarebChief Medical OfficerN/AN/AN/A
Mr. David LevisonExecutive Chairman & President of Pacific Edge Diagnostics USA32,29kN/A1960
Die Beträge haben den Stand 31. Dezember 2009 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limiteds ISS Governance QualityScore, Stand 1. Juni 2024, lautet 4. Die grundlegenden Scores sind Audit: 7, Vorstand: 2, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.